We’re heading to the ECVS Congress in Antwerp! PBC BioVet is proud to participate in the European College of Veterinary Surgeons (ECVS) Congress from July 3–5 in Antwerp, Belgium. 🧬 Visit us at Booth #20 to explore how OssiVet®, our advanced bone adhesive, is transforming orthopedic surgery in veterinary practice. 💬 Learn how this innovative solution can enhance fixation, facilitate, and support faster recovery — all while simplifying complex procedures. We look forward to connecting with you, sharing clinical insights, and discussing how bone adhesives can elevate your surgical outcomes. 📍Save the date and stop by Booth 20 — see you in Antwerp! #ECVS2025 #OssiVet #PBCBioVet #VeterinaryOrthopedics #BoneAdhesive #VetSurgery #Antwerp2025 #InnovationInSurgery #VeterinaryMedicine

The PBC Biomed Team are delighted to celebrate the success of another exceptional #ESTROT event following our time in Leeds last week. Our ‘Strengthening The Bond’ workshop on our #breakthrough bio-adhesive, OsStic®, attracted great interest and discussion, featuring a futuristic look at Bone Healing led by Prof. Thomas A. (Toney) Russell MD, including an interactive hands-on demonstration. As we begin the European roll-out of our ‘Strengthening the Bond’ educational platform, keynote presentations were delivered by Dr. Gerard Insley, Prof. Thomas A. (Toney) Russell MD. and researcher Srishti Agarwal on our developing technology. A sincere thank you to Prof. Peter Giannoudis for hosting and to the ESTROT organisers for all of their support — we’re already looking forward to ESTROT 2026! #ESTROT2025 #PBCBiomed #acceleratingmedicalinnovation #tissueregeneration #orthopaedics #traumatology

📢 Join Us for the OssiVet® Webinar – April 14, 2025! 🦴💻 We’re excited to invite veterinary professionals to our upcoming OssiVet® Educational Webinar on Monday, April 14th, 2025. Discover how OssiVet®, our advanced orthopedic bone bioadhesive, is transforming fracture management and joint stabilization in veterinary surgery. From science to real clinical cases, we’ll cover the benefits and techniques that help improve patient outcomes. ✅ Date: Monday, April 14, 2025 ✅ Time: 16:00-17:00 GMT / 17:00-18:00 CET ✅ Format: Online – FREE Registration Topics Include: 🔹 Science behind OssiVet® 🔹 Application techniques 🔹 Clinical case studies 🔹 Q&A with our experts 📩 Register now by messaging us or emailing [email protected] Don’t miss this opportunity to enhance your orthopedic practice! #OssiVet #VeterinaryOrthopedics #VetSurgery #Webinar #VeterinaryMedicine #Innovation #FractureRepair #PBCBioVet

PBC Biomed attend AAOS 2025 Thank you to the PBC Biomed Clinical Advisory Board for their support at the #AAOS event in San Diego last week! Dr Thomas A. (Toney) Russell MD, Dr John Tracy Watson, Dr Hassan Mir, MD, MBA and Professor Peter Giannoudis did a fantastic job of talking booth visitors through the application of our #breakthrough bio-adhesive OsStic®; as providing an insight on the potential clinical value of the material. Next stop, the 2025 European Society of Tissue Regeneration in Orthopaedics & Traumatology (ESTROT) meeting in May!

OssiVet® Now Available in EU We’re excited to announce that OssiVet®, our innovative Synthetic Adhesive Bone Substitute, is now available for use in domestic companion animals for orthopedic reduction, provisional fixation, and void filling of bone fractures or defects. OssiVet® is designed to make a difference in your practice by offering: • Simplified application for improved surgical outcomes. • Biomimetic Processes: Ossivet® bone substitutes are designed to mimic the natural adhesion, mechanical properties, and remodelling of bone, facilitating bone healing, defect repair, and implant fixation. • Supporting a variety of animal orthopaedic cases with confidence. 🎯 Interested in seeing OssiVet® in action? We’re offering exclusive product demonstrations to show how it can transform your practice. 👉 reach out to schedule your demo or to learn more about OssiVet®. [email protected] Let’s work together to enhance small animal orthopaedic care Stay tuned for more country availability and follow us. www.pbcbiomed.com/pbcbiovet #ossivet #PBCBiovet #VeterinaryInnovation #AnimalCare #animalorthopedics #EULaunch

The PBC Biovet Operations Team has reached a significant milestone with the preparation and release of our very first OssiVet® order! OssiVet®, our innovative veterinary bioadhesive bone substitute, is designed to support advanced orthopedic care for companion animals, combining safety, efficacy, and ease of use. This landmark achievement is a testament to our team’s hard work, dedication, and commitment to delivering innovative solutions for veterinary orthopedic Application/ Fixation. 🔹 State-of-the-art preparation: Our team ensures the highest quality standards throughout the development lifecycle. 🔹 Seamless execution: From production to distribution, every step reflects our passion for excellence. 🔹 Onward to veterinarians: OssiVet® is now on its way to revolutionize bone surgeries in veterinary practices. We are proud to contribute to advancing veterinary care and look forward to hearing success stories from veterinarians using OssiVet® in their practices. #VeterinaryInnovation #PBCBiovet #OssiVet #Orthopedicsurgery

We are delighted to announce that we will be continuing our ‘Strengthening the Bond’ education series at the Orthopaedic Trauma Association meeting in Montreal this week. Strengthening the Bond: Modern Biomaterials for Fracture Fixation and Bone Regeneration. Our global panel of surgeon advisors will discuss current hashtag#Biomaterials and their challenges, as well as plans for the first human implantation of OsStic®, a hashtag#Breakthrough Bio-Adhesive bone void filler technology. Speaker panel is as below: – Peter Giannoudis – John Tracy Watson – Hassan Mir, MD, MBA – Thomas A. (Toney) Russell MD The session will take place on Friday 23rd October at 12:45pm in room 514ABC. See below for further information – we look forward to seeing you there! #OTA2024 #strengtheningthebond #industrylunchseries #pbcbiomed #acceleratingmedicalinnovation #biomimeticinnovations

It was fantastic to welcome the Enterprise Ireland #DTIF consortium team to our Shannon Headquarters at the start of September for a project progress meeting. Thank you to Nicholas Dunne and the DCU postgraduate team, the Dolmen Design & Innovation team, as well as Jackie FitzGerald of Enterprise Ireland for making the trip! #DTIF #disruptivetechnology #OsStic #development #researchanddevelopment #enterpriseireland #acceleratingmedicalinnovation

PBC Biomed would like to welcome our two newest members to the Biomimetic Innovations Ltd team – Quality Specialist Annmarie Donnellan (left) and Director of Operations Ann Marie Ryan (right). We are delighted to have you both on board – exciting times ahead for BMI and the development of OsStic® Technology! #newhire #operations #biomimeticinnovations #acceleratingmedicalinnovation

Shannon, Ireland, February 12th 2024: Irish medical device company Biomimetic Innovations Ltd, an affiliate of PBC Biomed, announced ‘Breakthrough Device’ designation from the Food and Drug Administration FDA in January, for the development of a groundbreaking new bio-adhesive bone void filler technology called OsStic®.  PBC Biomed leads a consortium for this development project, which is comprised of Biodesign Europe and SFI Research Centre for Advanced Manufacturing (I-Form) at Dublin City University, and Dolmen Design & Innovation, a Dublin-based product design company. The project (2021 – 2024) is funded under the Disruptive Technologies Innovation Fund (DTIF), which is a €500 million fund established under the National Development Plan (NDP) in 2018 and led by the Department of Enterprise, Trade and Employment, and administered by Enterprise Ireland. The aim of the fund is to drive collaboration between Ireland’s world-class research base and industry, as well as facilitating enterprises to compete directly for funding in support of the development and adoption of these technologies.  Welcoming the announcement, Dr Imelda Lambkin, Disruptive Technologies and Innovation Department Manager, Enterprise Ireland commented; “This announcement is a great success for PBC Biomed and is testament to the capability and talent, vibrancy and international competitiveness of the Irish innovation and research system. In line with Enterprise Ireland’s strategy, this success will support the company to build on their existing capabilities, scale and create jobs. “The collaboration between Dublin City University, Dolmen Design & Innovation, Biomimetic Innovations, and PBC Biomed exemplifies the power of interdisciplinary efforts in research and development. The ‘Breakthrough Device’ designation by the FDA validates the promising trajectory of OsStic®, showcasing Ireland’s capability to lead in cutting-edge medical technologies. This achievement not only highlights the success of the project but also emphasizes the importance of sustained investment in disruptive technologies to foster innovation and elevate Ireland’s global standing in the medical device industry.” Professor Nicholas Dunne, Founding Executive Director of Biodesign Europe, Dublin City University and Funded Investigator in the SFI Research Centre for Advanced Manufacturing and SFI Centre for Advanced Materials and BioEngineering Research. “This announcement marks a major milestone in the evolution of calcium-based biomaterials. The proposed indication will be unique and for the first time will address all surgeon needs when dealing with complex fractures and allow for faster recovery times and greatly improved results for patients.” Gerard Insley, Chief Science Officer BMI. Learn more about DTIF here: https://lnkd.in/dHQ3_2vF About BMI Biomimetic Innovations Ltd, is an affiliate of PBC Biomed; a medical device company involved in design, development and manufacturing headquartered in Shannon, Ireland and with offices in Memphis, Tennessee and Chamonix, France.